The law under consideration “delinks” PBM compensation from manufacturer rebates in Medicare and requires flat administrative fees, certified at fair market value. It also mandates that rebates be passed through to health plan sponsors in the employer-sponsored market. This sounds appealing, but incentives matter. When compensation no longer depends on securing better terms, bargaining effort becomes a cost center rather than a profit center. PBMs will still compete for contracts, but competition on administrative fees isn’t the same as competition on aggressive price concessions and won’t lower drug prices.
BEST FOR SMALL SCHOOL FANS
，这一点在PDF资料中也有详细论述
Continue reading...
該區域的美國盟友也對特朗普貿易政策接下來的發展感到不確定。上週末，日本政府發言人表示，東京「將仔細研究這項裁決的內容以及特朗普政府的回應，並做出適當回應」。